Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

8.35
-0.1900-2.22%
Post-market: 8.31-0.0400-0.48%18:47 EDT
Volume:501.93K
Turnover:4.20M
Market Cap:581.56M
PE:-1.61
High:8.50
Open:8.40
Low:8.18
Close:8.54
Loading ...

Phathom Pharmaceuticals Inc expected to post a loss of $1.15 a share - Earnings Preview

Reuters
·
29 Apr

BRIEF-Phathom Pharmaceuticals To Report First Quarter 2025 Financial Results And Provide Business Update On Thursday, May 1, 2025

Reuters
·
23 Apr

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
21 Apr

Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

Press Release: Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Dow Jones
·
16 Apr

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
09 Apr

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Zacks
·
08 Apr

Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

Simply Wall St.
·
07 Apr

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
02 Apr

BRIEF-Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
02 Apr

Phathom Pharmaceuticals Stock Falls on CEO Switch

Dow Jones
·
02 Apr

Phathom Pharmaceuticals Names Basta President, CEO as Curran Resigns

Dow Jones
·
01 Apr

Phathom Pharmaceuticals Names Steven Basta CEO

MT Newswires Live
·
01 Apr

Phathom Pharmaceuticals appoints Basta as President, CEO

TIPRANKS
·
01 Apr

BRIEF-Phathom Pharmaceuticals Announces Leadership Succession

Reuters
·
01 Apr

Press Release: Phathom Pharmaceuticals Announces Leadership Succession

Dow Jones
·
01 Apr

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

GlobeNewswire
·
31 Mar

Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating

MT Newswires Live
·
20 Mar

Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges

TIPRANKS
·
11 Mar

Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
11 Mar